Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholland, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D., Burness, Kerry, Blow, Julian J. ORCID: https://orcid.org/0000-0002-9524-5849, Mehellou, Youcef and Muqit, Miratul M. K. (2018) The anthelmintic drug niclosamide and its analogues activate the Parkinson's disease associated protein kinase PINK1. ChemBioChem, 19 (5). pp. 425-429. ISSN 1439-4227
Full text not available from this repository. (Request a copy)Abstract
Mutations in PINK1, which impair its catalytic kinase activity, are causal for autosomal recessive early-onset Parkinson's disease (PD). Various studies have indicated that the activation of PINK1 could be a useful strategy in treating neurodegenerative diseases, such as PD. Herein, it is shown that the anthelmintic drug niclosamide and its analogues are capable of activating PINK1 in cells through the reversible impairment of the mitochondrial membrane potential. With these compounds, for the first time, it is demonstrated that the PINK1 pathway is active and detectable in primary neurons. These findings suggest that niclosamide and its analogues are robust compounds for the study of the PINK1 pathway and may hold promise as a therapeutic strategy in PD and related disorders.
Item Type: | Article |
---|---|
Additional Information: | Funding: Wellcome Trust. Grant Numbers: WT096598MA, 101022/Z/13/Z; Medical Research Council. Grant Number: MC_PC_16041. |
Uncontrolled Keywords: | drug discovery,membranes,mitochondria,neurodegenerative diseases,proteins |
Faculty \ School: | |
Depositing User: | LivePure Connector |
Date Deposited: | 10 Jun 2024 14:30 |
Last Modified: | 25 Sep 2024 17:51 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/95457 |
DOI: | 10.1002/cbic.201700500 |
Actions (login required)
View Item |